BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31792356)

  • 21. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
    Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
    Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
    Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
    Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
    Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
    Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.
    Dong K; Yin L; Wang Y; Jia L; Diao X; Huang X; Zhou L; Lin D; Sun Y
    Hum Pathol; 2024 Jun; 148():87-92. PubMed ID: 38653403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
    Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
    Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
    Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
    Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.
    da Silva SIO; Domingos TA; Kupper BEC; De Brot L; Aguiar Junior S; Carraro DM; Torrezan GT
    Exp Mol Pathol; 2023 Apr; 130():104855. PubMed ID: 36736685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
    Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
    Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NTRK fusion-positive colorectal cancer in Japanese population.
    Yonemaru J; Hashimoto T; Takayanagi D; Naka T; Yatabe Y; Kanemitsu Y; Shiraishi K; Sekine S
    Pathol Int; 2021 May; 71(5):355-359. PubMed ID: 33631044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
    Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
    Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The coding microsatellite mutation profile of PMS2-deficient colorectal cancer.
    Bajwa-Ten Broeke SW; Ballhausen A; Ahadova A; Suerink M; Bohaumilitzky L; Seidler F; Morreau H; van Wezel T; Krzykalla J; Benner A; de Miranda NF; von Knebel Doeberitz M; Nielsen M; Kloor M
    Exp Mol Pathol; 2021 Oct; 122():104668. PubMed ID: 34302852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
    Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
    Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NTRK fusion in Japanese colorectal adenocarcinomas.
    Yamashiro Y; Kurihara T; Hayashi T; Suehara Y; Yao T; Kato S; Saito T
    Sci Rep; 2021 Mar; 11(1):5635. PubMed ID: 33707574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
    Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
    Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
    Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
    Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
    [No Abstract]   [Full Text] [Related]  

  • 40. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
    Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.